effects of Buspirone on functional dyspepsia

The effects of Buspirone on patients with functional dyspepsia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180405039198N1

Enrollment

Registered

2019-06-08

Start date

2018-12-22

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional dyspepsia. Functional dyspepsia

Interventions

Intervention 1: Intervention group: The patients in this group will receive 3 tablets of Buspirone 5 mg (Iran Daru company) daily during the first month and three 10 mg tablets during the second month

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Having dyspeptic symptoms for at least 3 months Normal upper gastrointestinal endoscopy

Exclusion criteria

Exclusion criteria: History of psychological diseases History of gastric or esophageal surgery Having Celiac disease

Design outcomes

Primary

Measure	Time frame
Therapeutic effect. Timepoint: Before starting the study and then after two months. Method of measurement: Questionnair.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTarang Taghvaei

Mazandaran University of Medical Sciences

tarang_taghvaei@yahoo.com+98 11 3377 1760

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026